Inferra AI / Company / BRVE
Braveheart Bio, Inc.
BRVE · Health Care
Last earnings Sep 8, 2026
AI analysis
Q2 2026 · reported Sep 8, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
Net loss was $15.0 million, and net loss attributable to common stockholders, after a deemed dividend upon the issuance of Series A preferred stock, was $18.6 million or $2.51 net loss per share, basic and diluted, for the three months ended June 30, 2026, compared to a net loss of $0.4 million, or $0.14 net loss per share, basic and diluted, for the same period in 2025.
Event summary
We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Net loss was $15.0 million, and net loss attributable to common stockholders, after a deemed dividend upon the issuance of Series A preferred stock, was $18.6 million or $2.51 net loss per share, basic and diluted, for the three months ended June 30, 2026, compared to a net loss of $0.4 million, or $0.14 net loss per share, basic and diluted, for the same period in 2025.
SEC original ↗Braveheart Bio, Inc. — Earnings release (8-K exhibit)EX-99Sep 8, 2026
The deemed dividend of $3.6 million is a non-cash charge representing the excess of the estimated fair value of the Series A preferred stock issued in April 2026 over the $1.00 per share purchase price.
SEC original ↗Braveheart Bio, Inc. — Earnings release (8-K exhibit)EX-99Sep 8, 2026
Based on the current operating plan, Braveheart Bio estimates that its existing cash and cash equivalents, together with the net proceeds from its IPO, will be sufficient to fund its projected operating expenses and capital expenditure requirements into 2029.
SEC original ↗Braveheart Bio, Inc. — Earnings release (8-K exhibit)EX-99Sep 8, 2026
As of September 8, 2026, the issuance date of the condensed financial statements, the Company expects that its cash and cash equivalents, including the proceeds from its IPO, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its cash needs through a combination of equity offerings, debt or royalty financings, and collaborations.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
As the Company s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Strategy & priorities
About Braveheart Bio Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
SEC original ↗Braveheart Bio, Inc. — Earnings release (8-K exhibit)EX-99Sep 8, 2026
All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
The Company will need additional financing to support its continuing operations and pursue its growth strategy.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
If the Company is unable to obtain sufficient funding, the Company will be forced to delay, scale back or discontinue some or all of its research and development programs, product portfolio expansion efforts or commercialization efforts, which could adversely affect its business prospects.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
This discussion and analysis and other parts of this Quarterly Report contains forward-looking statements based upon our current plans and strategy for our business that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Risks & headwinds
Food and Drug Administration and comparable foreign regulatory authorities risks related to establishing and maintaining Braveheart Bio s intellectual property protections and risks related to the competitive landscape for Braveheart Bio s product candidates as well as the other risks and uncertainties described under the heading Risk Factors section in Braveheart Bio s upcoming Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and any subsequent filings Braveheart Bio makes with the Securities and Exchange Commission.
SEC original ↗Braveheart Bio, Inc. — Earnings release (8-K exhibit)EX-99Sep 8, 2026
Legal Proceedings 34 Item 1A.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions described in Risk Factors and elsewhere in this Quarterly Report.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
and Chinese laws and geopolitical developments may adversely affect our business, results of operations, financial condition and prospects.
SEC original ↗Braveheart Bio, Inc. — 10-Q Quarterly report10-QSep 8, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
3 documentsEarnings releases
1 document- Q2 2026
- EX-99BRVE
Presentations
0 documentsNo presentations for Braveheart Bio, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Braveheart Bio, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.